Jeffrey H. Cooper MBA ’80 has been appointed to the board of directors of ProNAi Therapeutics, a clinical-stage oncology company advancing novel therapeutics for patients with cancer. Cooper has served as an independent consultant for life science companies since January 2014. Previously, he served at KaloBios Pharmaceuticals and BioMarin Pharmaceutical. He has also served as VP of finance at Matrix Pharmaceutical.